Engineered immune cells take on liver cancer in new trial
Disease control
Recruiting now
This study tests a new treatment called ECT204 for adults with advanced liver cancer that has not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The trial will enroll 60 pe…
Phase: PHASE1, PHASE2 • Sponsor: Eureka Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC